Outcomes of Systemic Therapy for @entity1 with XXXX .

@entity1 @entity632 @entity6023 @entity8253 @entity5 @entity5426
BACKGROUND: @entity5426 ( @entity5426 ) are rare @entity5 of vascular origin with a variable behavior and overall poor prognosis. We sought to assess the outcomes of @entity1 treated for metastatic disease. METHODS: We performed a retrospective analysis of 119 @entity1 treated for metastatic @entity5426 . Outcomes and efficacy measurements of the first and subsequent lines of treatment were analyzed. RESULTS: Median age was 61 years, and the most frequent primary sites were chest wall/breast (31%), viscera (22%) and head/neck (20%). Seventy-three (61%) and 46 (39%) @entity1 received >= 2 and >= 3 lines of therapy, respectively. The most commonly used agents included @entity6023 and @entity8253 . Median overall survival was 12.1 months. Median times to @entity5 progression were 3.5 months for first line, 3.7 months for second line and 2.7 months for third line. Among 48 @entity1 evaluable per RECIST, the overall response rate to first line was 30% and <10% in subsequent lines. @entity632 , liposomal @entity632 and @entity6023 resulted in similar response rates and survival, and there was no apparent benefit for combination chemotherapy. CONCLUSION: Despite reasonable response rates in the first-line setting, benefit from systemic therapy is short-lived in metastatic @entity5426 , and outcomes are poor. @entity632 , liposomal @entity632 and @entity6023 are reasonable and appropriate choices for monotherapy.    2015 S. Karger AG, Basel.
